AVAGLIM 8mg / 4mg film-coated tablets medication leaflet

A10BD04 rosiglitazone + glimepiride • Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs

Rosiglitazone+glimepiride is a combination medication used in the treatment of type 2 diabetes mellitus. Rosiglitazone increases insulin sensitivity in cells, while glimepiride, a sulfonylurea derivative, stimulates insulin secretion from the pancreas.

This combination is taken orally, usually once daily, and is indicated for patients who fail to control their blood sugar levels through diet, exercise, or other antidiabetic medications. It is effective in lowering blood glucose levels and preventing diabetes-related complications.

Common side effects include hypoglycemia, weight gain, nausea, and fluid retention. In rare cases, severe adverse reactions such as heart failure or allergic reactions may occur. Regular monitoring of blood glucose levels and cardiac function is essential.

Rosiglitazone+glimepiride is an effective therapeutic option for patients with type 2 diabetes, offering improved glycemic control through complementary mechanisms of action.

General data about AVAGLIM 8mg / 4mg

Substance: rosiglitazone + glimepiride

Date of last drug list: 01-07-2013

Commercial code: W51440004

Concentration: 8mg / 4mg

Pharmaceutical form: film-coated tablets

Quantity: 84

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Concentrations available for rosiglitazone + glimepiride

4mg/4mg, 8mg/4mg

Other substances similar to rosiglitazone + glimepiride